As of 2026-04-04, the Relative Valuation of Apellis Pharmaceuticals Inc (APLS) is 13.14 USD. This relative valuation is based on P/E multiples. With the latest stock price at 40.41 USD, the upside of Apellis Pharmaceuticals Inc based on Relative Valuation is -67.5%.
The range of the Relative Valuation is 10.38 - 16.65 USD.
| Range | Selected | |
| Trailing P/E multiples | 25.9x - 30.5x | 28.2x |
| Forward P/E multiples | 24.0x - 30.3x | 27.2x |
| Fair Price | 10.38 - 16.65 | 13.14 |
| Upside | -74.3% - -58.8% | -67.5% |
| Date | P/E |
| 2026-04-02 | 100.72 |
| 2026-04-01 | 100.67 |
| 2026-03-31 | 100.27 |
| 2026-03-30 | 42.60 |
| 2026-03-27 | 42.30 |
| 2026-03-26 | 43.97 |
| 2026-03-25 | 44.17 |
| 2026-03-24 | 42.94 |
| 2026-03-23 | 43.79 |
| 2026-03-20 | 42.90 |
| 2026-03-19 | 44.79 |
| 2026-03-18 | 44.59 |
| 2026-03-17 | 46.91 |
| 2026-03-16 | 47.03 |
| 2026-03-13 | 47.21 |
| 2026-03-12 | 45.84 |
| 2026-03-11 | 48.30 |
| 2026-03-10 | 48.95 |
| 2026-03-09 | 49.82 |
| 2026-03-06 | 50.02 |
| 2026-03-05 | 50.22 |
| 2026-03-04 | 49.50 |
| 2026-03-03 | 50.25 |
| 2026-03-02 | 51.59 |
| 2026-02-27 | 52.24 |
| 2026-02-26 | 53.94 |
| 2026-02-25 | 53.39 |
| 2026-02-24 | 55.16 |
| 2026-02-23 | 56.01 |
| 2026-02-20 | 55.53 |
| 2026-02-19 | 56.83 |
| 2026-02-18 | 55.33 |
| 2026-02-17 | 53.76 |
| 2026-02-13 | 54.09 |
| 2026-02-12 | 54.96 |
| 2026-02-11 | 55.61 |
| 2026-02-10 | 56.28 |
| 2026-02-09 | 56.90 |
| 2026-02-06 | 58.55 |
| 2026-02-05 | 56.23 |
| 2026-02-04 | 57.70 |
| 2026-02-03 | 58.12 |
| 2026-02-02 | 56.90 |
| 2026-01-30 | 56.28 |
| 2026-01-29 | 57.45 |
| 2026-01-28 | 57.50 |
| 2026-01-27 | 54.36 |
| 2026-01-26 | 54.81 |
| 2026-01-23 | 54.21 |
| 2026-01-22 | 54.83 |